Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Youjia, Kawaguchi, Atsushi, Takeshita, Masaru, Sekiya, Takeshi, Hirohama, Mikako, Yamashita, Akio, Siomi, Haruhiko, Murano, Kensaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Accelerated Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846482/
https://www.ncbi.nlm.nih.gov/pubmed/33524396
http://dx.doi.org/10.1016/j.jbc.2021.100346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846482/
https://www.ncbi.nlm.nih.gov/pubmed/33524396
http://dx.doi.org/10.1016/j.jbc.2021.100346

Ejemplares similares